Standard - But Fair? Anti-Dilution Clauses in Today's Venture Market

By Adv. Roee Weinberger, Founding Partner, Weinberger & Co., 2025

 Executive Summary

Anti-dilution clauses have traditionally been treated as a minor, “standard” part of venture term sheets. In today’s market, where down rounds are common rather than exceptional, that assumption is no longer sustainable.

Recent data from Carta, Fenwick, and the Shibolet–Fenwick surveys show that down rounds now represent roughly 20% of financings in global markets and in Israel – the highest rates in over a decade. At the same time, broad-based weighted-average anti-dilution has become near-universal across venture transactions, with full ratchet protection appearing mainly in distressed deals.

As a result, anti-dilution provisions are being triggered frequently and have a real impact on cap tables. In most structures, they shift the economic cost of a down round away from preferred investors and onto common shareholders – primarily founders, employees, and early unprotected investors. This effect is particularly problematic at later stages, where investors often control the board and key strategic decisions but remain significantly shielded from valuation risk.

The article argues that:

• Anti-dilution no longer operates as a rare safety net; it is now a routine instrument that reallocates losses in roughly one in five financings.

• The traditional allocation of protection – strong for investors at all stages, weak or non-existent for common – can distort incentives, discourage honest pricing, complicate rescue financings, and undermine employee motivation.

• In some cases, complex down-round features may also cause conversion options to be classified as derivative liabilities under IFRS, creating financial-reporting volatility and regulatory friction.

• A more mature approach would tailor protection to stage and circumstance, share the burden more evenly in distress, and connect enhanced protection to continued investor support.

The conclusion is not that anti-dilution is illegitimate, but that it should be treated as an explicit allocation of risk and responsibility – not as untouchable boilerplate – especially in a market where down rounds have become a structural feature rather than an anomaly.

 Standard – But Fair? Anti-Dilution Clauses in Today’s Venture Market

Venture term sheets are full of clauses that attract hours of negotiation: valuation, liquidation preference, control rights, and board composition. And then there is the small, quiet paragraph labeled “anti-dilution.” It rarely gets top billing in the room, yet it decides who absorbs the cost when a company’s valuation falls.

For years, it was possible to treat this clause as boilerplate. Down rounds were rare, the market was “up only”, and the conversion formula looked like theoretical algebra. That world has changed. Carta, which tracks thousands of private companies, reports that in 2023, roughly 19–20% of all primary venture fundings on its platform were down rounds in every single quarter – the highest rates since at least 2018.

Silicon Valley surveys tell a similar story. Fenwick’s Q4 2023 Silicon Valley Venture Capital Survey shows that down rounds climbed from just 1% of financings in Q1 2022 to 13% in Q4 2023 – the highest level since the early months of the Covid-19 crisis. In Israel, a joint Shibolet–Fenwick survey found that the rate of down rounds in 2023 reached 20%, almost double Silicon Valley’s 11% and the highest level observed since the 2008 financial crisis.

In other words, anti-dilution protections are no longer a remote contingency. They are being triggered in a meaningful share of financings. Once that is acknowledged, the clause can no longer be dismissed as harmless boilerplate. It becomes a design choice about who carries which risks when valuations fall.

This article looks at anti-dilution through that lens. It is written for everyone who sits around the cap table – founders, executives, investors, LPs, and board members – and focuses on three questions:

1. How does anti-dilution actually move value between shareholders?

2. Is the traditional allocation of protection still defensible in a mature ecosystem?

3. What alternative structures could better align incentives without abandoning downside protection altogether?

 From Boilerplate to Capital Allocation

Almost all modern venture financings contain price-based anti-dilution protection. Deal surveys in North America show that broad-based weighted-average anti-dilution is overwhelmingly dominant compared with narrow-based or full ratchet mechanisms; for example, a major Canadian report found that over 96% of preferred shares issued in its sample carried broad-based weighted-average protection. US practice surveys from firms such as Wilson Sonsini similarly report broad-based weighted-average anti-dilution in roughly 90% of deals. European data from PwC and BVK confirm the same pattern: broad-based weighted-average clauses are now the standard, with full ratchet reserved for a minority of transactions, often distressed or highly structured.

Guides aimed at growth-equity investors reach similar conclusions: recent summaries of global practice estimate that around 60% of venture deals in 2023 used weighted-average anti-dilution as the primary protection against down rounds. Israeli surveys, combining data from Shibolet and Fenwick, describe anti-dilution rights as a standard component of preferred share financings, with Israeli deal terms largely converging on US norms.

In short, a typical tech company that has raised several rounds of preferred capital will almost certainly have multiple layers of anti-dilution protection embedded in its cap table. When a down round occurs, those clauses do not merely “adjust formulas”. They transfer value.

 How the Mechanism Moves Value Around

Anti-dilution provisions are often dismissed as “just math”. In substance, they are about who pays when the price goes down.

Consider a simplified example. A company raises Series A at 1.00 per share, issuing 10 million preferred shares to investors. There are 10 million ordinary shares outstanding (founders and ESOP). The fully diluted ownership is 50% preferred, 50% common.

Later, the company raises a down round at 0.50 per share. New investors buy 20 million preferred shares. Without anti-dilution, the original Series A shares are unaffected; the new investors simply own a larger slice of the pie.

Now add a broad-based weighted-average anti-dilution clause. The exact formula varies, but in many standard versions, the Series A conversion price will be reset from 1.00 to somewhere in the neighborhood of 0.75. That means that, upon conversion, each Series A share will yield roughly 1.33 ordinary shares instead of one.

On an as-converted basis, the Series A investors now hold around 13.3 million ordinary equivalents instead of 10 million. The “extra” 3.3 million shares are effectively taken from everyone else: the founders, the employees, and any other shareholders who do not benefit from protection. The company does not receive a single additional dollar in exchange for this shift.

The specific numbers will differ from deal to deal, but the general pattern is constant. Anti-dilution does not create or destroy value. It reallocates losses from the protected preferred to the unprotected parts of the cap table. In most venture-backed companies, those unprotected parts consist primarily of common shareholders: founders, employees, and early angels.

When this mechanism is layered across several financing rounds, the cumulative effect can be striking. By the time a company faces a serious down round after multiple preferred financings, the common stock has often become the primary buffer that absorbs almost all of the adjustment.

 What Anti-Dilution Was Trying to Fix

This asymmetry did not appear from nowhere. Anti-dilution emerged to solve a real concern about early-stage risk.

In the classic story, early investors write cheques when there is little more than a team and a slide deck. The probability of failure is high, information is incomplete, and valuations are largely aspirational. If a future round is priced materially below the last valuation, it can seem unfair that those who took the greatest risk on incomplete information should be punished most severely.

Anti-dilution was framed as a fairness adjustment. The idea was that founders and early investors together had set an ambitious price in the last round; if it later proved unrealistic, both should share in the consequences. Adjusting the conversion price of the preferred would partially hedge the investor’s exposure to “over-optimistic” pricing without guaranteeing a full recovery.

There is still legitimacy in that logic in the earliest stages of a company’s life. Information asymmetry is real. Choices about initial valuation can be crude. Investors who commit capital before there is a product or revenue do take a special kind of risk.

Over time, however, the context changed. Late-stage investors today often have analytics teams, access to extensive market data, and deep visibility into a company’s operations. At Series C or D, the board is frequently dominated by investor representatives; strategic plans, budgets, and major financing decisions require investor approval. The assumption that investors are passive, under-informed passengers in the car is no longer accurate.

Yet the legal text of anti-dilution clauses has barely evolved. The same level of protection that was originally designed for seed-stage investors now regularly appears in late-stage rounds where investors exercise considerable control. That is where the tension emerges most acutely.

 Two Different Risks Hiding in One Clause

When a down round happens, it is tempting to treat all such events as economically identical. In reality, at least two different types of risk are being bundled together.

The first is valuation error. The previous round was priced too high relative to what the company was truly worth at the time. Perhaps the market was exuberant, comparables were distorted, or competitive dynamics were misunderstood. The new round is essentially a correction of an earlier mispricing.

The second is business deterioration. The company’s fundamental prospects have worsened. Maybe unit economics broke down as the business scaled, regulation changed, product-market fit was weaker than anticipated, or competition intensified. The new round reflects a genuine decline in underlying value.

Anti-dilution provisions treat both scenarios identically. They do not ask whether the down round corrects a previous pricing bubble or reflects a real destruction of value. In both cases, the clause shields investors from part of the loss and shifts a disproportionate share of the pain onto common shareholders.

One can argue that in the first scenario – a pure valuation correction – this may be acceptable: those who enjoyed the benefits of an inflated paper valuation should help absorb the correction. In the second scenario, particularly at later stages where investors have held board seats and veto rights for years, the justification is much weaker. When the people who approved strategy, budgets, and key hires are also the primary economic beneficiaries of a down-round adjustment, questions of fairness and alignment become unavoidable.

 When Investors Hold the Steering Wheel

By the time a company reaches advanced stages of financing, the relationship between founders and investors has changed. Investors are no longer simply capital providers observing from afar. They are often board members, committee chairs, and key voices on strategic decisions.

If, after several years of such involvement, the company finds itself in distress and requires a down round, the story that “investors took pure risk and therefore deserve full protection” is difficult to sustain. In substance, risk and responsibility have been shared.

Yet in many deals, the investors’ economic rights still look as if the company were permanently in seed mode. Late-stage preferred shares frequently carry senior liquidation preferences, participation rights, broad vetoes, and robust anti-dilution protection. Common shareholders, by contrast, hold residual claims that are deeply subordinated, largely unprotected, and structurally exposed to any anti-dilution adjustments.

Israeli surveys underline this concentration of economic rights in the hands of preferred investors. Shibolet’s multi-year reports consistently show higher rates of senior liquidation preferences, participation, and other investor-friendly features in Israeli deals than in Silicon Valley comparables, even before factoring in down-round adjustments.

In this environment, the traditional model – in which common shareholders are treated as the automatic shock absorber for every repricing – becomes less persuasive. It is not only a question of moral fairness. It is a question of whether long-term incentives make sense for a company that wants to retain its founders and senior team through turbulence.

 What Data Shows: Down Rounds Are Now Routine

The shift in market conditions over the last few years reinforces this point.

On Carta’s platform, which covers tens of thousands of venture-backed companies primarily in the US but increasingly globally, down rounds accounted for nearly 20% of all primary fundings in Q1 2023, about 19% in Q2, and above 18% in Q3. Carta’s Q4 2023 State of Private Markets report notes that down rounds continued to represent between 19% and 20% of venture deals in each quarter of 2023 – four consecutive record highs for the period since 2018.

In Silicon Valley specifically, the Fenwick survey shows the percentage of down rounds rising steadily from 1% of financings in Q1 2022 to 11–13% through 2023, depending on the quarter. The trend is particularly pronounced at later stages: Series E and beyond are disproportionately represented among down-round companies.

In Israel, the 2023 Shibolet yearly survey records that down rounds accounted for 20% of financings, up from 9% in 2022, and almost double the Silicon Valley rate for the same period. The survey notes explicitly that this is the highest rate of down rounds observed in the Israeli market since 2008.

Taken together, these data points disprove the comfortable assumption that anti-dilution clauses “rarely” come into play. They are now, in many markets, in the money in roughly one out of every five financings.

When contractual protection starts being invoked that often, its distributional consequences can no longer be waved away as a rare edge case.

 Second-Order Effects Most People Miss

Once anti-dilution is seen as an active instrument, rather than a theoretical safety net, a set of second-order effects becomes visible.

One effect is on pricing discipline. Strong anti-dilution softens the downside of overpaying in an earlier round. If a fund knows that a substantial part of any future valuation drop will be pushed onto founders and employees, the marginal cost of joining a slightly inflated round today is reduced. The clause can, unintentionally, reward aggressive pricing behavior and weaken internal incentives to challenge frothy valuations.

Another effect is on board-level decision-making in distress. In a down-round negotiation, investor directors who enjoy robust anti-dilution may be economically better off favoring a heavily dilutive rescue at a low price – which triggers a large adjustment in their favor – over alternatives such as a more balanced recapitalization or a modest sale. The legal duty of loyalty does not disappear, but the alignment of economic interests is skewed in ways that are not always obvious from the outside.

There is also the impact on employees. A down round alone is demoralizing; it tells the team that the market values the company less than before. When anti-dilution is triggered on top of that, employees may find that their already underwater options now represent a much smaller share of the cap table, with any refreshed grants diluting everyone else again. The people expected to work hardest on the turnaround can end up with the weakest long-term economic stake.

From a fundraising perspective, heavy anti-dilution can make it harder to attract new rescue capital. New investors will model how much of their money is truly going into the business and how much it is effectively compensating existing investors through conversion price adjustments. Where too much of the round is “consumed” by anti-dilution, new investors may either demand very senior, punitive terms or simply decline to participate, pushing the company closer to insolvency or a distressed sale.

Finally, there are accounting and regulatory angles. Under IFRS, the presence of certain down-round features in convertible instruments can cause the conversion option to fail the “fixed-for-fixed” test for equity classification, because the number of shares to be delivered varies depending on future share issues. When that happens, the conversion feature (or in some cases the whole instrument) may need to be accounted for as a derivative liability measured at fair value through profit and loss. This can introduce significant volatility into financial statements, complicate bank covenants, and create obstacles for future IPOs.

None of these effects means that anti-dilution should disappear. They do mean that the clause has to be treated as a live economic lever rather than as a harmless remnant of market standard language.

 Legal and Governance Considerations in Israel

Beyond economics and accounting, the structure of anti-dilution interacts with corporate law. Israeli law, like many legal systems, contains doctrines aimed at preventing oppression of minority shareholders and abuse of control. In a scenario where investors have accumulated strong control rights over several financing rounds, founders and employees have been heavily diluted, and a down round is structured in a way that further entrenches investor economics at the expense of common shareholders, questions about fairness and proper exercise of power will naturally arise.

The Shibolet–Fenwick surveys document that Israeli deals tend to feature more investor-friendly terms (for example, a higher incidence of senior and participating preferences) than Silicon Valley deals in comparable periods. When these features are combined with strong anti-dilution in a distressed environment, the residual value of common stock can become extremely thin.

This is not an argument that every aggressive down-round adjustment constitutes oppression. Courts are rightly careful not to second-guess commercial judgments made in good faith. But from a board-governance perspective, it is prudent to recognize that extreme outcomes – where those who hold control rights are almost completely insulated from the downside they helped create – carry legal as well as reputational risk.

 Towards Smarter Risk-Sharing

If the current pattern is imperfect, what might an improved approach look like? There is no single “correct” formula, but several principles can guide a more balanced design.

One principle is stage sensitivity. Strong anti-dilution may be more justifiable for early rounds where information is thin, and outcome distributions are wide. As a company matures, the justification for full protection weakens as investor influence and visibility increase. Contracts can reflect this by capping the total adjustment, introducing sunsets (after which protection falls away), or linking protection to continued participation in future rounds.

Another principle is shared burden. Instead of pushing nearly all adjustments into the common, recapitalizations and distressed financings can explicitly allocate part of the pain to each preferred series. This can be achieved by waiving some anti-dilution rights, flattening parts of the liquidation stack, converting some preferred to common, or earmarking a portion of the round for management and employee top-ups funded collectively by investors.

A third principle is alignment-based protection. Enhanced protection can be conditioned on actions that increase alignment, such as participation in rescue financings. Investors who continue to support the company in hard times can be granted stronger protection than those who decline to invest further but still wish to enjoy full anti-dilution benefits.

There is also a pragmatic constraint: simplicity. Over-engineered clauses may trigger unwanted accounting consequences and confuse both boards and employees. Clear, moderately conservative structures that can be explained in one page – including a simple “what happens if there is a 50% down round” scenario – are often more valuable than mathematically elegant but opaque mechanisms.

 Practical Implications for Founders, Investors, and Boards

For founders, the key is to treat anti-dilution as part of the price of capital, not as an incidental detail. A higher valuation achieved at the cost of very strong anti-dilution and heavy preferences can produce worse outcomes than a slightly lower valuation with a cleaner capital structure, especially once the probability of a future down round is realistically acknowledged.

For investors, the question is whether aggressive protection truly serves long-term performance. Funds ultimately report cash returns, not theoretical downside insulation. Portfolios filled with over-structured companies in which management has lost meaningful upside tend to deliver disappointing distributions, even if headline valuations look impressive for a while.

For boards, the practical discipline is transparency. Before approving a down round or a complex recap, directors should insist on clear cap-table scenarios showing how each class of security is affected under different structures. Independent directors, where they exist, can play a critical role in balancing competing interests and ensuring that long-term value creation is not sacrificed to short-term protection of any single constituency.

 Conclusion: From Formula to Responsibility

Anti-dilution clauses will not disappear from venture term sheets. Nor should they. Early-stage capital carries genuine risk, and mechanisms that share that risk between founders and investors are an integral part of the venture model.

What has changed is the context. Down rounds are now a regular feature of the market. Preferred share terms have become more protective. Investors are more deeply involved in company governance than ever before. In this environment, the traditional pattern – strong protection for investors across all stages, funded largely by common shareholders – looks less like a neutral market convention and more like a structural choice that deserves to be examined explicitly.

A mature ecosystem can handle that examination. It can accept that early-stage risk may justify robust protection, while also recognizing that late-stage control carries responsibilities as well as rights. It can design anti-dilution mechanisms that protect capital without hollowing out the incentives of those who build the company.

The anti-dilution clause is a small paragraph with a large shadow. Treating it as boilerplate is no longer an option. Treating it as a conscious allocation of risk – and designing it accordingly – is part of the next stage of growth for venture markets in Israel and beyond.

References (selected)

1. Carta – State of Private Markets (Q1–Q4 2023). Quarterly reports on private venture financings, including down-round frequency and valuation trends.

2. Fenwick & West – Silicon Valley Venture Capital Survey (Q1 2022–Q4 2023). Data on financing terms, including the prevalence of down rounds by quarter and stage.

3. Shibolet & Co. / Fenwick – “Trends in Legal Terms in Venture Financings in Israel – 2023 Yearly Survey.” Analysis of Israeli venture deal terms, including down-round frequency and comparison to Silicon Valley.

4. Torys LLP – Venture Financing Report (2020). Empirical study of Canadian venture financings, reporting broad-based weighted-average anti-dilution in over 96% of preferred issuances.

5. Wilson Sonsini – Private Company Financing Trends (1H 2012 and later updates). Surveys of US venture financing show broad-based weighted-average anti-dilution in roughly 90% of deals.

6. BVK / PwC – Venture Capital Market Studies (Germany/Europe, 2022–2023). Overviews of European VC deal terms, including prevalence and structure of anti-dilution provisions.

7. Growth Equity Interview Guide – “Anti-Dilution Protection: A Guide for Investors & Founders” (2023). Summary of global practice noting weighted-average anti-dilution in around 60% of venture deals.

8. BDO – IFRS Accounting Standards in Practice: Convertible Notes (2024/25). Discussion of down-round features, equity vs. liability classification under IFRS, and the “fixed-for-fixed” test.

 *This article is provided for general information purposes only and does not constitute legal or investment advice. Specific advice should be sought in relation to any particular transaction or circumstance.